Clinical Trial Update: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating measurable residual disease-guided post-transplant maintenance with elranatamab for multiple myeloma. The study is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING